70
Participants
Start Date
September 1, 2024
Primary Completion Date
November 1, 2028
Study Completion Date
June 1, 2029
Blood sample
"blood test to assess :~* human leukocyte antigen (HLA)-B\*5701 status to identify risk of allergy or hypersensitivity to abacavir (the study treatment)~* IFN-signature ans IFN-alpha dosage~* human immunodeficiency virus (HIV), hepatitis B virus (HBV) and Hepatitis C virus (HCV) serologies~* Human chorionic gonadotropin (βHCG)~* HERVs dosage A biological collection will also be created. The total volume of blood collected specifically for the research for the entire duration of the study is 62.5 millilitre (mL) maximum."
Treatment :Abacavir 600 mg/lamivudine 300 mg
Patients randomised to the experimental arm will be required to take 1 tablet (600 mg lamivudine and 300 mg abacavir) once daily for 6 months in addition to their usual treatment.
Lupus Impact Tracker questionnaire
Patients will be asked to complete the Lupus Impact Tracker questionnaire at visit V1 (randomisation visit), visit 3 (at 6 months of treatment) and visit 4 (12 months after visit 1).
Groupe Hospitalier Pellegrin-CHU de Bordeaux, Bordeaux
CHU Nord de Grenoble - Albert Michallon, Grenoble
CHU de Saint-Etienne - Hôpital Nord, Saint-Priest-en-Jarez
Hôpital Claude Huriez, Lille
CHU de Clermont-Ferrand - Hôpital Gabriel Montpied, Clermont-Ferrand
Hôpital de la Croix-Rousse (HCL), Lyon
Hôpital Lyon Sud (HCL), Pierre-Bénite
Hôpital Edouard Herriot (HCL), Lyon
Hôpital Femme-Mère-Enfant (HCL), Bron
Hôpital Necker-Enfants malades, Paris
Hôpital Pitié-Salpêtrière, Paris
Hospices Civils de Lyon
OTHER